Immunome Reports Third-Quarter 2026 Financial Results and Business Update
Immunome reported financial results for the quarter ended September 30, 2026, and provided a business update.
Story updates
09:02:20 PM UTC
SquawkNews
Immunome reported Q3 2026 financial results and provided a pipeline update. The release gives no financial figures; the company said IM-1340's Phase 1 trial is planned by year-end and updated IM-1021 data are expected December 14, 2026.Material DetailsContext by AI AnalystThis update follows multip…
09:13:42 PM UTC
SquawkNews
Immunome reported a net loss of $85.8 million for the third quarter of 2026, with no collaboration revenue. The company ended September with $461.6 million in cash, cash equivalents and marketable securities. It also reported regulatory progress for varegacestat and clinical pipeline advances, incl…
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a business update.“We made significant progress across our onc…